Metrics as of 10/13/2026, 06:37 PM (Berlin time), refresh in progress.
Benitec Biopharma Stock
Benitec Biopharma Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jerel A. Banks
- Employees
- 24
- Market cap
- $283 M
- IPO
- 24/06/2014
- Web
- benitec.com
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing…
Benitec Biopharma stock: price history
1D
-4.1%
1W
-8.6%
1M
-26.5%
6M
-42.4%
YTD
-39.8%
1Y
-48.3%
2Y
-17.3%
5Y
-86.7%
10Y
-97.8%
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~21% weaker price swings than usual
Ask the agents about Benitec Biopharma
Analyst assessment of Benitec Biopharma
PRICE TARGET LOW
US$17.00
CONSENSUS
US$21.00
MEDIAN
US$21.00
PRICE TARGET HIGH
US$25.00
0
STRONG BUY
7
BUY
1
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 15/09/2026
Benitec Biopharma stock metrics
P/E
-8.28
P/B
2.13
EV/EBITDA
-2.31
RETURN ON EQUITY
-7.2%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
97.5%
FLOAT SHARES
33,478,711
AVG. DAILY VOLUME (30D)
178,563
Insider transactions (SEC)
BUCHI J KEVIN
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Benitec Biopharma stock
What does Benitec Biopharma do?
Benitec Biopharma Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jerel A. Banks, the company employs around 24 people.
The IPO was on 24/06/2014; the stock trades on NASDAQ under the ticker BNTC.
What do analysts say about Benitec Biopharma stock?
8 analysts rate the stock, the consensus is Buy (as of 15/09/2026).
The average price target is US$21.00, ranging from US$17.00 to US$25.00, with a median of US$21.00.
This is an external assessment, not a statement by Market Jury.
When does Benitec Biopharma report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly -21% stronger than usual.
Does Benitec Biopharma pay a dividend?
Yes. The last dividend was US$0.00 per share, ex-date 01/06/2018, paid on 08/06/2018.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Benitec Biopharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Benitec Biopharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess Benitec Biopharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.